Ethionamide and the Quiet Battle Against the World’s Oldest Disease

Ethionamide has an almost unyielding quality. It was discovered in 1956 and has been on pharmacy shelves for almost 70 years. Despite the emergence and disappearance of newer, more ostentatious antibiotics, it has refused to retire. The majority of patients are unaware of it.

The majority of physicians hardly ever prescribe it unless they work in TB wards or in areas where TB still spreads like a slow tide through communities. However, ethionamide is frequently the medication that doctors, sometimes reluctantly, turn to when treatments don’t work and the conventional regimens don’t work against resistant strains of Mycobacterium tuberculosis.

Key Information	Details
Drug Name	Ethionamide (ETA / ETH)
Drug Class	Thioamide antibiotic
Brand Name	Trecator
Discovered	1956
FDA Approval	1965
Chemical Formula	C8H10N2S
Molar Mass	166.24 g/mol
Melting Point	164–166 °C
Route of Administration	Oral (by mouth)
Typical Adult Dose	15–20 mg/kg daily (usually 500 mg to 1 g)
Half-Life	2 to 3 hours
Protein Binding	~30%
Primary Use	Multidrug-resistant tuberculosis
Mechanism	Inhibits mycolic acid synthesis (prodrug activated by ethA)
Listed On	WHO Essential Medicines List
Manufacturer	Wyeth Pharmaceuticals (acquired by Pfizer, 2009)
Common Side Effects	Nausea, vomiting, hepatotoxicity, neuropathy

It’s not a coincidence that they are reluctant. The pattern is familiar to anyone who has observed a patient taking ethionamide. The nausea strikes early. then throwing up. A minor but damaging detail that makes daily compliance truly challenging is the metallic, sulfurous taste that some patients report lingering for hours. Doctors frequently advise taking it with food or delaying the dosage until before bed—small changes that, in their simplicity, resemble folk medicine.

However, the adverse effects are not limited to the stomach. About 5% of patients experience liver toxicity, which typically appears within the first three months, sometimes later, and sometimes without warning. Peripheral neuropathy gradually develops. Pyridoxine is frequently administered in addition to it as a sort of biochemical buffer because reports of mood swings and even mental disorders have been made.

The fact that ethionamide is still relevant may indicate more about the state of tuberculosis treatment than it does about the medication. TB hasn’t gone away. In parts of South Asia, sub-Saharan Africa, and Eastern Europe, multidrug-resistant strains are quietly outpacing the medical infrastructure built to contain them. Ethionamide, structurally similar to isoniazid but activated through a different bacterial pathway, fills a gap that newer drugs haven’t fully closed. Isoniazid is still helpful even when first-line medications don’t work because its cross-resistance rate is only about 13%.

The chemistry has a more subdued backstory. Since ethionamide is a prodrug, an enzyme known as ethA must activate it inside the bacterium. The genetic switch that suppresses ethA expression, ethR, has been the subject of years of research in the hopes that blocking ethR would increase the effectiveness of ethionamide at lower dosages. The project is still in progress. Whether it will translate into a meaningful clinical benefit is still unclear, but the interest itself suggests the drug isn’t quite finished evolving.

Walking through any TB clinic in a high-burden country, you notice things. Pill blister packs were arranged by the dozen. The way nurses count out tablets, sometimes seven or eight at once, knowing patients will swallow them with reluctance. Ethionamide is often somewhere in that mix, a yellow crystalline tablet with a faint sulfide odor, prescribed not because it’s pleasant but because the alternative is worse.

Investors and pharmaceutical executives don’t talk much about ethionamide. This is not a breakthrough story or a profit story. Because the world still needs it, this workhorse medication is listed on the World Health Organization’s List of Essential Medicines. That in and of itself says something. Ethionamide survives because it is practical, flawed, and essential in a sector that is fixated on innovation.

It’s difficult to ignore the irony. Despite having side effects that would probably never pass modern approval standards, a medication from the 1950s is still crucial in the fight against one of the oldest diseases in human history. Decades ago, tuberculosis was supposed to be eradicated. It wasn’t. Until then, ethionamide will continue to appear, silently performing the tasks that no one else wants to perform.